Linked Life Data

3019238

Source:http://linkedlifedata.com/resource/pubmed/id/3019238

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3019238rdf:typepubmed:Citationlld:pubmed
pubmed-article:3019238lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3019238lifeskim:mentionsumls-concept:C0018557lld:lifeskim
pubmed-article:3019238lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:3019238lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:3019238lifeskim:mentionsumls-concept:C1415900lld:lifeskim
pubmed-article:3019238lifeskim:mentionsumls-concept:C1418867lld:lifeskim
pubmed-article:3019238lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:3019238pubmed:issue1lld:pubmed
pubmed-article:3019238pubmed:dateCreated1986-10-6lld:pubmed
pubmed-article:3019238pubmed:abstractTextThe efficacy of a novel consensus form of human alpha interferon designated IFN-alpha Con1 was evaluated against herpesvirus infections in vitro and in vivo. At comparable antiviral concentrations, natural lymphoblastoid IFN, IFN-alpha Con1, the molecular subtype IFN-alpha, and the hybrid IFN-alpha AD(Bgl) obtained by recombinant DNA methods conferred similar protection against herpes simplex virus type 1 and type 2 (HSV-2) infections of human cells in vitro. Whereas 7 X 10(5) U of IFN-alpha AD(Bgl) administered in 7 intraperitoneal (i.p.) doses between -4 and 96 h relative to infection protected 90% of mice from a lethal HSV-2 infection, a similar treatment regimen with IFN-alpha Con1 conferred no protection. Systemic HSV-2 infection of hamsters was rapidly lethal, but a single i.p. treatment with 10(6) U of either IFN-alpha Con1 or IFN-alpha AD(Bgl) was highly effective and protected 90 and 75% of animals, respectively, when given 6 h before infection; treatment with IFN-alpha Con1 protected 45% of animals when administered 10 h after infection. In addition, IFN-alpha Con1 was highly protective against acute cervicovaginal HSV-2 infection of hamsters when administered either in a single i.p. dose of 10(6) U at -6 or 10 h relative to infection or in multiple i.p. doses of 10(6) U between -6 and 120 h relative to infection. Protection was manifested by a delay in the onset of and a reduction in duration of infection, a reduction in the number of positive cervicovaginal infections, and an increase in the survival rate.lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:languageenglld:pubmed
pubmed-article:3019238pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:citationSubsetIMlld:pubmed
pubmed-article:3019238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3019238pubmed:statusMEDLINElld:pubmed
pubmed-article:3019238pubmed:monthJullld:pubmed
pubmed-article:3019238pubmed:issn0066-4804lld:pubmed
pubmed-article:3019238pubmed:authorpubmed-author:StebbingNNlld:pubmed
pubmed-article:3019238pubmed:authorpubmed-author:BanerjeeKKlld:pubmed
pubmed-article:3019238pubmed:authorpubmed-author:FishE NENlld:pubmed
pubmed-article:3019238pubmed:authorpubmed-author:LevineH LHLlld:pubmed
pubmed-article:3019238pubmed:issnTypePrintlld:pubmed
pubmed-article:3019238pubmed:volume30lld:pubmed
pubmed-article:3019238pubmed:ownerNLMlld:pubmed
pubmed-article:3019238pubmed:authorsCompleteYlld:pubmed
pubmed-article:3019238pubmed:pagination52-6lld:pubmed
pubmed-article:3019238pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:meshHeadingpubmed-meshheading:3019238-...lld:pubmed
pubmed-article:3019238pubmed:year1986lld:pubmed
pubmed-article:3019238pubmed:articleTitleAntiherpetic effects of a human alpha interferon analog, IFN-alpha Con1, in hamsters.lld:pubmed
pubmed-article:3019238pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3019238lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3019238lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3019238lld:pubmed